Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

ABSTRACT:

Importance

Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.

Objective

To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.

Design, setting, and participants

A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers.

Interventions

Women with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n = 8506) or placebo (n = 8102). Women with prior hysterectomy received CEE alone (0.625 mg/d) (n = 5310) or placebo (n = 5429). The intervention lasted a median of 5.6 yea

SUBMITTER: Manson JE 

PROVIDER: S-EPMC3963523 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature